An Exploratory Phase II Study to Demonstrate the Safety and Efficacy of A4250 in Children With Cholestatic Pruritus
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs A 4250 (Primary)
- Indications Alagille syndrome; Biliary atresia; Cholestasis; Intrahepatic cholestasis; Pruritus
- Focus Adverse reactions
- Sponsors Albireo AB
- 03 Oct 2017 According to an Albireo Pharma media release, data will be presented at the American Association for the Study of Liver Diseases (AASLD) 2017..
- 21 Aug 2017 According to an Albireo Pharma media release, results from this trial will be presented at the The Liver Meeting 2017.
- 22 Apr 2017 Results from this trial were presented at The International Liver Congress 2017, according to an Albireo Pharma media release.